EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nanomedicine for the management of rheumatoid arthritis: current status and prospective therapeutic approaches

Neha Gupta, Abdul Rahaman Shaik, Ananda Kumar Chettupalli, Sarad Pawar Naik Bukke, Narayana Goruntla

Discover Medicine · 28.04.2025 · 2 (1)

DOI: 10.1007/s44337-025-00316-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discover Medicine, online erschienen am 28.04.2025. Verfasst von Neha Gupta und 4 weiteren Autor:innen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanotechnology has rapidly become a viable instrument for investigating innovative methods, ranging from properly identifying many disorders to treating intricate medical situations. Due to their adjustable surface qualities and similar size dimensions, custom-designed nanoparticles can now interact with cellular targets and diverse diseases more effectively. The primary objective of medicine distribution is to guarantee that pharmaceuticals are supplied only to the necessary areas, minimizing side effects and unintended consequences. Rheumatoid Arthritis (RA) is a persistent inflammatory condition that results in the gradual deterioration of bone as well as cartilage, resulting in significant disability, reduced life, and elevated mortality rates. Advanced treatment for RA notably decreased the disease’s progression and enhanced the life quality for numerous individuals. Conversely, individuals can occasionally achieve remission of their illnesses and maintain them without the continuous need for immunosuppressants. Many patients either develop tolerance to or exhibit non-responsiveness to existing treatments. Consequently, novel pharmaceutical strategies for the treatment of RA remain necessary. In contrast to conventional pharmaceuticals, nanocarriers are engineered to deliver therapy directly to the joint inflammation site, thus circumventing systemic and adverse side effects. Drugs previously deemed excessively hazardous for systemic administration are presently undergoing re-evaluation by scholars. This article summarizes contemporary nanotechnology methods for managing RA and discusses potential advancements in nanotherapeutic approaches.

Zitieren

APA

Gupta, N., Shaik, A. R., Chettupalli, A. K., Bukke, S. P. N., & Goruntla, N. (2025). Nanomedicine for the management of rheumatoid arthritis: current status and prospective therapeutic approaches. Discover Medicine, 2(1). https://doi.org/10.1007/s44337-025-00316-7

Vancouver

Gupta N, Shaik AR, Chettupalli AK, Bukke SPN, Goruntla N. Nanomedicine for the management of rheumatoid arthritis: current status and prospective therapeutic approaches. Discover Medicine. 2025;2(1). doi:10.1007/s44337-025-00316-7

BibTeX
@article{Gupta2025,
  author = {Gupta, Neha and Shaik, Abdul Rahaman and Chettupalli, Ananda Kumar and Bukke, Sarad Pawar Naik and Goruntla, Narayana},
  title = {Nanomedicine for the management of rheumatoid arthritis: current status and prospective therapeutic approaches},
  journal = {Discover Medicine},
  year = {2025},
  volume = {2},
  number = {1},
  doi = {10.1007/s44337-025-00316-7}
}
Kostenlos starten →